Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle
Open Access

Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy

Mandeep Atwal, Emma L. Lishman, Caroline A. Austin and Ian G. Cowell
Molecular Pharmacology January 2017, 91 (1) 49-57; DOI: https://doi.org/10.1124/mol.116.106054
Mandeep Atwal
Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne. United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma L. Lishman
Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne. United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline A. Austin
Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne. United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian G. Cowell
Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne. United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    MPO inhibition reduces the level of TOP2-DNA covalent complexes formed by etoposide in NB4 cells. (A and B) Succinylacetone (SA) abolished MPO activity (A) and reduced mature protein levels in NB4 cells (B); NB4 cells were treated with 200 µM SA for 48 hours and assayed for MPO activity (A) and MPO protein level by Western blotting of whole cell extracts (B). Blots were quantified by densitometry. (C and D) TOP2-DNA covalent complexes were quantified by TARDIS analysis using antibodies specific to TOP2A (C) or TOP2B (D). Integrated fluorescence values were determined per nucleus (at least 500 nuclei per treatment per replicate experiment). From these, median values were obtained for each treatment and means of the medians were calculated from replicate experiments (n = 3). Data are expressed as a percentage of the mean value obtained with 100 μM etoposide in the absence of SA, ±S.E.M. Integrated fluorescence data corresponding to an individual experiment are also shown in Supplemental Fig. 3, A and B. *P < 0.05.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Expression of active MPO in K562 cells increases the level of etoposide-stabilized TOP2-DNA covalent complexes. (A) Comparison of MPO activity (left) and MPO immunofluorescence (right) in K562 cells, two MPO-expressing K562-derived cell lines (K562MPO line4 K562MPO line5), and in NB4 cells. (B) K562 and K562MPO cell lines were incubated with 10 or 100 µM Etoposide or a vehicle control for 1 hour. Etoposide-stabilized TOP2-DNA complexes were quantified by TARDIS analysis using antibodies specific for TOP2A or TOP2B as described for Fig. 1. Numbers of replicates are indicated. *P < 0.05; **P < 0.01; ***P < 0.001.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    MPO activity results in raised levels of etoposide-induced H2AX phosphorylation. (A) NB4 cells were pretreated for 48 hours with SA (200 µM) then incubated with etoposide (10 or 100 µM). (B) K562 and K562MPO cell lines were incubated with 10 and 100 µM etoposide or dimethyl sulfoxide vehicle control. For both (A) and (B), γH2AX was quantified by immunofluorescence. Analysis was carried out as described for TARDIS analysis in Fig. 1. Data are expressed relative to the mean values obtained with 100 μM etoposide in the absence of SA (A) or in wild-type parental K562 cells (B). Numbers of replicates are indicated. *P < 0.05; **P < 0.01; ***P < 0.001.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    MPO activity enhances mitoxantrone-induced TOP2-DNA covalent complex formation and H2AX phosphorylation. (A and B) NB4 cells were pretreated with 200 μM SA for 48 hours followed by a 1-hour incubation with 0.5 or 1 μM mitoxantrone, or a vehicle control. TOP2-DNA covalent complexes and γH2AX were quantified as in Figs. 1 and 3. Data are expressed relative to the mean values obtained with 1 μM mitoxantrone in the absence of SA. (C) Quantification of MPO activity in K562MPO line 2 compared with NB4 and parental K562 cells. (D) MPO expression in K562 cells results in enhanced mitoxantrone-induced TOP2-DNA protein complex formation. Data are expressed relative to the mean value obtained for parental K562 cells treated with 1 μM mitoxantrone. Numbers of replicates are indicated. *P < 0.05; **P < 0.01; ***P < 0.001.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Glutathione depletion increases etoposide-mediated TOP2-DNA covalent complex formation and H2AX phosphorylation. (A) BSO preincubation (150 μM, 4.5 hours) resulted in 70% reduction of total and reduced glutathione in NB4 cells. (B–D) NB4 cells were incubated in the presence or absence of SA (200 μM) for 48 hours, BSO (150 μM) for 4.5 hours, with both or with neither, followed by addition of 10 or 100 μM etoposide for 1 hour. TARDIS and γH2AX assays were performed as described in Figs 1 and 3. Numbers of replicates are indicated. *P < 0.05; **P < 0.01; ***P < 0.001.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Glutathione depletion potentiates mitoxantrone-mediated TOP2 covalent complex formation and H2AX phosphorylation. NB4 cells were preincubated with SA, BSO, or both as described for Fig 4, followed by addition of 1 μM mitoxantrone for 1 hour. TOP2A TARDIS (A), TOP2B TARDIS (B), and γH2AX assays (C) were performed as described in Figs 1 and 3. *P < 0.05; **P < 0.01; ***P < 0.001.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Direct MPO inhibition reduces the level of TOP2-DNA covalent complexes formation and H2AX phosphorylation induced by etoposide or mitoxantrone in NB4 cells. (A and B) NB4 cells were pretreated with MPO inhibitors PF-1355 (10 μM, 4 hours) or MPOi-II (5 μM, 4 hours) before adding 10 or 100 μM etoposide or a vehicle control for 1 hour. (C and D) NB4 cells were pretreated with MPO inhibitors as in (A and B) before adding 0.5 or 1 μM mitoxantrone or a vehicle control for 1 hour. TOP2-DNA covalent complexes (A and C) and γH2AX (B and D) were quantified as in Figs 1 and 3. Numbers of replicates are indicated. **P < 0.01; ***P < 0.001.

Additional Files

  • Figures
  • Data Supplement

    Data Supplement

    Files in this Data Supplement:

    • Data Supplement -

      Supplemental Figure 1 - MPO is expressed in CD34+ bone marrow cells

      Supplemental Figure 2 - (A) Enzymatic oxidation of etoposide

      Supplemental Figure 3 - (A& B) Example of a single replicate experiment of the TARDIS TOP2A (A) and TOP2B (B) covalent complex quantification shown in Fig 1 C and D

      Supplemental Figure 4 - (A) Inhibition of MPO activity in NB4 cells by PF-1355 and MPOi-II

      Supplemental References

      Supplemental Table 1 - MPO activity affects etoposide and mitoxantrone-induced TOP2 CC and γH2AX levels and associated statistics

      Supplemental Table 2 - Effect of MPO inhibition and GSH depletion on etoposide and mitoxantrone-induced TOP2 CC and γH2AX levels and associated statistics

      Supplemental Table 3 - Comparison of the effects of succinylacetone and direct MPO inhibitors on etoposide and mitoxantrone-induced TOP2-DNA covalent complexes and H2AX phosphorylation

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 91 (1)
Molecular Pharmacology
Vol. 91, Issue 1
1 Jan 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

MPO Increases TOP2 Poison-Mediated DNA Damage

Mandeep Atwal, Emma L. Lishman, Caroline A. Austin and Ian G. Cowell
Molecular Pharmacology January 1, 2017, 91 (1) 49-57; DOI: https://doi.org/10.1124/mol.116.106054

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

MPO Increases TOP2 Poison-Mediated DNA Damage

Mandeep Atwal, Emma L. Lishman, Caroline A. Austin and Ian G. Cowell
Molecular Pharmacology January 1, 2017, 91 (1) 49-57; DOI: https://doi.org/10.1124/mol.116.106054
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • α-Conotoxin Binding Site on the GABAB Receptor
  • Upacicalcet binds to the amino acid binding site of CaSR
  • Characterization of GRD and LCCH3 from Human Louse
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics